FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA Stock

DE000MB1CZL0

Real-time Bid/Ask 08:03:21 2024-06-07 am EDT
68.97 ^EUR / 69.58 ^EUR	+1.88%

Current month	+4.99%
1 month	+2.24%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ZEALAND PHARMA A/S

Chart FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA

Latest news about ZEALAND PHARMA A/S

Zealand Pharma A/S : announces that Boehringer Ingelheim's survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis	04:44am	PU
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis	04:39am	GL
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL	Jun. 06	GL
Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL	Jun. 06	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-07	69.18	+1.74%
24-06-06	68	+13.37%
24-06-05	59.98	-9.51%
24-06-04	66.28	+0.53%
24-06-03	65.93	+1.79%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 05:18 am EDT

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	ZEALAND PHARMA A/S
Issuer	Morgan Stanley
WKN	MB1CZL
ISIN	DE000MB1CZL0
Date issued	2022-12-12
Strike	325.6 kr
Maturity	Unlimited
Parity	0.65 : 1
Emission price	10 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	94.34 €
Lowest since issue	9.4 €
Spread	0.61 €
Spread %	0.88%

Company Profile

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.

Sector

More about the company

Ratings for Zealand Pharma A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Zealand Pharma A/S

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

651 DKK

Average target price

785.6 DKK

Spread / Average Target

+20.67%

Consensus